83 results about "Bone metastasis" patented technology

The invention discloses application of rehmannia extracellular vesicles in preparation of a medicine for improving breast cancer bone metastasis bone injury, and belongs to the technical field of biological medicine. The preparation method comprises the following steps: cleaning the root tuber of a fresh rehmannia plant, adding a PBS (Phosphate Buffer Solution), crushing, and filtering by gauze to remove large-particle impurities; performing high-speed centrifugation on the filtrate to remove insoluble residues, then performing ultra-high-speed centrifugation to collect precipitates, re-suspending the precipitates, purifying the precipitates by adopting PEG (Polyethylene Glycol), and centrifugally collecting the precipitates, thereby obtaining the rehmannia extracellular vesicles. The rehmannia extracellular vesicles can effectively target bones, promote proliferation of bone-related cells and remarkably reduce bone injury caused by bone metastasis of breast cancer; bone protection treatment is carried out on breast cancer bone metastasis through the Chinese herbal medicine vesicles sourced from rehmannia, a safe and effective treatment scheme is provided for improving the pathological osteolysis problem caused by breast cancer bone metastasis, a new thought and technical support are provided for prevention and treatment of tumor bone metastasis related diseases, and good clinical transformation prospects are achieved.

The invention provides a Falcarindiol derivative, preparation thereof and application of the Falcarindiol derivative in preparation of medicines for preventing and / or treating bone diseases. The structural general formula of the Falcarindiol derivative is as shown in formula I in the specification. Experimental results show that the Falcarindiol derivative can significantly inhibit osteoclast differentiation, and is expected to be used for preparing novel drugs for preventing and / or treating osteoporosis, osteoporosis fracture, osteolysis, periprosthetic osteolysis, tumor bone metastasis, inflammatory bone loss, periodontitis inflammatory bone resorption and other bone diseases. # imgabs0 #

The invention discloses a prostate cancer bone metastasis identification method and system based on enhanced Raman spectroscopy, and the method comprises the steps: carrying out the preprocessing of one-dimensional surface enhanced Raman spectroscopy data obtained in advance, generating a multi-scale time-frequency characteristic pattern through continuous wavelet transform, and mapping an original signal to a time-frequency domain; performing frequency band division and conquer on a multi-scale time-frequency characteristic graph obtained after continuous wavelet transform, decomposing the multi-scale time-frequency characteristic graph into high-frequency, intermediate-frequency and low-frequency sub-bands, and extracting characteristics through a directional convolution kernel; segmenting the extracted feature map into block-level representations and injecting learnable position codes; generating complementary query and key vectors from the partitioned features through dual-path projection, and realizing local feature enhancement in combination with a local window mask and a dynamic gating parameter; and outputting a classification result through a Transform encoder and a full connection layer. The invention provides an efficient solution for high-sensitivity and real-time detection of prostatic cancer osseous metastasis, and can be widely applied to the field of biomedical spectrum analysis.

Among other things, the present disclosure provides antibodies and antigen-binding fragments thereof, conjugates, compositions, and methods thereof that can be used for various purposes, including treating conditions, disorders, or diseases including cancer, e.g., prostate cancer. In some embodiments, antibodies and antigen-binding fragments thereof comprise one or more bone-targeting moieties, e.g., one or more bone-targeting peptides. In some embodiments, antibodies and antigen-binding fragments thereof, conjugates, compositions, and methods thereof can be used to treat bone metastases.

The present invention discloses a biomarker for assisting in the diagnosis of bone metastasis of lung adenocarcinoma. The present invention specifically provides an application of a biomarker or a detection reagent thereof in the preparation of a product for assisting in the diagnosis or early screening of bone metastasis of lung adenocarcinoma, wherein the biomarker is AA and / or ANGPTL4. The present invention applies AA and / or ANGPTL4 to the diagnosis of bone metastasis of lung adenocarcinoma for the first time, and provides a simple, non-invasive, and long-term available detection method through serum testing; compared with the existing technology, the present invention can achieve earlier diagnosis of bone metastasis, and avoids the health risks brought by radiation, and has a high clinical application value; in short, the present invention provides a new biomarker combination for the early diagnosis of bone metastasis of lung adenocarcinoma, which is expected to provide more accurate guidance for the clinical treatment of patients, and is of great significance for the long-term monitoring of tumor metastasis.

The application relates to the field of image processing and discloses a bone metastasis detection and positioning system and method based on SPECT bone imaging. The system extracts and processes multi-scale features of a to-be-detected image through a feature pyramid network to obtain a multi-scale feature map; then extracts metabolic features, morphological features and uptake mode features from the multi-scale feature map through a bone-specific feature model, and gradually fuses the metabolic features, the morphological features and the uptake mode features to obtain a bone-specific enhanced feature map; then extracts and fuses features of the bone-specific enhanced feature map through a mixed feature fusion model to obtain mixed fusion features; finally, the mixed fusion features are subjected to probability reasoning and double-uncertainty quantization processing through a probability reasoning network to determine a bone metastasis detection result, high-precision detection and positioning of bone metastasis lesions are realized, and the problems that existing technologies cannot effectively identify different size lesions and lack global perception ability are effectively solved.

The present invention discloses the application of CIR1 as a molecular marker in the diagnosis, treatment and prognosis evaluation of lung cancer bone metastasis, and belongs to the field of medical tumor diagnosis and treatment. The present invention found that CIR1 is highly expressed in tissues and cells of lung cancer bone metastasis, and is accompanied by a poor prognosis. In vivo and in vitro experiments confirmed that CIR1 downregulation can significantly inhibit the proliferation and migration ability of lung cancer cells, thereby inhibiting bone metastasis; at the same time, CIR1 downregulation can significantly inhibit the differentiation and maturation of lung cancer cells on osteoclasts, greatly reducing the occurrence of osteolytic destruction. Therefore, the present invention proposes to use a reagent for detecting the expression level of CIR1 in the preparation of a kit for detecting whether lung cancer has bone metastasis and / or a prognostic kit for predicting the tendency of lung cancer bone metastasis; and to use a CIR1 inhibitor in the preparation of a drug for preventing, alleviating and / or treating lung cancer bone metastasis, providing a new idea for the diagnosis, prognosis and treatment of lung cancer bone metastasis.

The application discloses a prostate cancer bone metastasis risk prediction diagnosis device and relates to the technical field of prostate cancer diagnosis. The application comprises a diagnosis table, two support rods are symmetrically arranged on one side of the diagnosis table, support plates are arranged on the sides of the two support rods away from each other, an adjusting assembly for adjusting the positions of the support plates is arranged on the support rods, a connecting block is fixed at one end of the diagnosis table, a movable groove is arranged in the connecting block, movable blocks are fixed at the bottom ends of the support rods, and the movable blocks are slidably connected in the movable groove. When rectal digital examination is needed for a patient, the patient is laid on the diagnosis table, the bent parts of the legs of the patient are respectively arranged on the two support plates, the two movable blocks are driven to move away from each other through a driving mechanism, the legs of the patient are bent and separated, and the patient is in a supine position, so that rectal digital examination in a supine position is facilitated.

This invention relates to the field of biological testing and discloses a plasma polypeptide marker, COL1A2, associated with tumor bone metastasis and pain, and its applications. To address the difficulties in early diagnosis of bone cancer pain and tumor bone metastasis, this study examined circulating COL1A2 levels in plasma and found that it was significantly upregulated in patients with bone metastasis and pain, and correlated significantly with clinical pain scores and tumor stage. Using enzyme-linked immunosorbent assay (ELISA) technology, a sensitive and specific COL1A2 detection method was established, capable of identifying the occurrence and stage of bone cancer pain and tumor bone metastasis with high predictive efficacy of 0.95 and 0.94, respectively. This assay is low-cost and simple to operate, making it suitable for clinical application. It provides scientific basis and technical support for screening high-risk populations, early diagnosis of bone metastasis, pain staging, and personalized treatment. This invention is of great significance for optimizing diagnostic and treatment strategies for patients with bone cancer pain and improving clinical translation efficiency.

The application discloses application of an inhibitor targeting SLC7A7 in preparation of a drug for treating lung cancer bone metastasis, and the inhibitor targeting SLC7A7 is a small molecule compound SLCi18. The application firstly verifies high expression of SLC7A7 in lung cancer bone metastasis cells and lung cancer bone metastasis clinical tissues, and silencing the expression of SLC7A7 can inhibit the development of lung cancer bone metastasis; the small molecule compound SLCi18 as the inhibitor targeting SLC7A7 can inhibit the function of SLC7A7 in transporting methionine, and inhibit lung cancer bone metastasis; and the application provides a new target and treatment strategy for lung cancer bone metastasis.

The invention is suitable for the technical field of medical image processing and artificial intelligence, and provides a urinary system tumor bone metastasis diagnosis method based on deep learning and bone positioning, and the method comprises the steps: collecting and preprocessing multi-modal medical data containing PET / CT images; segmenting a skeleton region by adopting a deep learning model, and realizing focus segmentation in the skeleton region; a lightweight skeleton segmentation network is constructed, and efficient and fine skeleton segmentation is realized through an encoder-decoder structure; pET metabolic features, CT morphological features and texture features are extracted and fused, and a radiomics feature matrix is constructed; carrying out cancer species specificity analysis based on the radiomics characteristic matrix, and constructing an intelligent diagnosis model by utilizing a machine learning algorithm; and finally, outputting a structured report containing the focus position, the type, the cancer classification and the diagnosis confidence. According to the invention, through lightweight network design and multi-modal feature fusion, the efficiency and accuracy of skeleton segmentation and focus diagnosis are significantly improved, and the method is suitable for clinical real-time auxiliary diagnosis.

The invention belongs to the technical field of gene detection, and particularly relates to a prostate cancer bone metastasis diagnostic kit based on gene methylation detection and application of the prostate cancer bone metastasis diagnostic kit. The invention proves that the bone metastasis and non-bone metastasis of the prostate cancer can be effectively distinguished by PCR methylation detection or joint detection based on AKR1B1, RASSF2 and other genes, and a new thought is provided for clinical diagnosis and typing of the bone metastasis of the prostate cancer.

The application discloses a kind of whole body SPECT lung cancer bone imaging data processing method and system, it is related to image processing technical field, comprising: the whole body SPECT lung cancer bone imaging data is input into the improved UNet network after training, local texture feature is extracted by profile wave decomposition module, local texture feature is fused with original image, and the image feature is extracted by inputting fusion feature into UNet encoder;Using the UNet decoder of adding profile wave feature splicing and reconstruction strategy to the extracted image feature, obtains lung cancer bone metastasis lesion area.The application can improve the feature extraction capability of bone imaging lesion segmentation method under low resolution and fuzzy boundary condition.

The invention relates to a CSF1R family inhibitor with a structure as shown in a formula (Ia) or a formula (Ib) and application of the CSF1R family inhibitor in pharmacy. The compound disclosed by the invention can be widely applied to preparation of drugs for treating tumors, autoimmune diseases, metabolic diseases or metastatic diseases related to CSF1R, PDGFRa and KIT kinase; the compound can be used for preparing medicines, especially medicines for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic diseases, neurodegenerative diseases, metastasis of primary tumor sites or bone metastatic cancer, and is expected to be developed into a new generation of CSF1R, PDGFRa and KIT kinase inhibitor medicines. # imgabs0 #

The invention belongs to the technical field of bioengineering, and discloses a method for constructing a bone-affinity mouse hepatoma cell line with bone metastasis characteristic, which comprises the following steps: digesting a mouse hepatoma cell line Hepa1-6 with pancreatin for 5 minutes, adding into a complete medium to stop digestion, centrifuging for 5 minutes at normal temperature by 300g, resuspending into 1 million cells / 100mu l by using PBS, and transferring into a 1.5 ml EP tube; after the mouse is anesthetized, shaving off hair at the chest of the mouse by using a shaver with the abdomen facing upwards, fixing the mouse on an operation table, sucking 100 [mu] l of cell suspension by using an insulin needle, inserting the needle from the intersection point of the left-side xiphoid process and the lower costal margin, and slowly injecting cells after active blood return is seen; the bone metastasis formation condition of the lower limb bone Hepa1-6 of the mouse is monitored regularly through an SPECTRAL Lago X small animal living body imaging system, isoflurane is used as an anesthetic, and it is guaranteed that the shooting time and the exposure condition of each time of monitoring are consistent; after obvious bone metastasis is formed, obvious mobility inconvenience of the mouse is observed; through multi-generation in-vivo screening, the mouse liver cancer cell line with strong bone affinity is obtained.

The application belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating lung cancer bone metastasis and application thereof. The main active ingredients of the traditional Chinese medicine composition include, in mass parts, 20-40 parts of radix codonopsis, 20-40 parts of poria, 20-40 parts of astragalus, 10-30 parts of atractylodes, 10-20 parts of licorice, 10-30 parts of curcuma, 10-20 parts of pinellia, 5-10 parts of dried tangerine or orange peel, 20-40 parts of oldenlandia, 10-30 parts of psoralea, 10-30 parts of drynaria, 10-30 parts of epimedium, and 10-20 parts of jackinthepulp. Animal experiments show that the traditional Chinese medicine composition can not only inhibit primary tumor growth, but also slow down tumor progression of bone metastasis. When combined with a chemotherapy drug, the traditional Chinese medicine composition can not only significantly enhance the tumor inhibition effect of the chemotherapy drug, but also significantly prolong the survival time of mice, relieve weight loss and organ toxic side effects caused by the chemotherapy drug.

The invention discloses a drug for combined treatment of breast cancer bone metastasis, the drug comprises two active components, namely a first active component and a second active component, the first active component is Bufalin and its pharmaceutically acceptable salt, prodrug and derivative, and the second active component is RANKL targeted drug; bufalin and a derivative thereof are combined with an RANKL targeted drug for use, the Bufalin and the derivative thereof are synergistically complementary, and the Bufalin is used for regulating and controlling a tumor microenvironment, reducing secretion of high bone metastatic breast cancer cells HMGB1 and inhibiting differentiation of mononuclear / macrophages in bone marrow to osteoclasts, so that occurrence and development of breast cancer bone metastasis are inhibited; the RANKL targeted drug can specifically block an OPG / RANK / RANKL signal channel, inhibit osteoclast activation, reduce bone destruction and block vicious circle of bone metastasis; when the two active ingredients are combined for use, the effect of inhibiting breast cancer bone metastasis is obviously better than that of single use of any active ingredient, the occurrence of breast cancer bone metastasis can be effectively prevented and delayed, the progress of bone metastasis focus is controlled, and the occurrence risk of bone related events is reduced.

This invention, belonging to the field of biological detection technology, discloses a marker and predictive diagnostic kit for luminal breast cancer bone metastasis based on circCCDC50 in tumor vesicles. Specifically, it discloses the use of circCCDC50 as a biomarker in the preparation of a product for the diagnosis / prediction of breast cancer bone metastasis. This invention proposes, for the first time, the use of circCCDC50 as a biomarker for luminal breast cancer bone metastasis. This circRNA can serve as a supplementary marker for the detection of luminal breast cancer bone metastasis and avoid missed detection of luminal breast cancer bone metastasis due to small metastatic lesions. circCCDC50 provides a broad and valuable predictive indicator for luminal breast cancer bone metastasis.

The present application relates to a marker IBSP of lung cancer bone metastasis and application thereof. Specifically, the present inventors found that IBSP is highly expressed in both plasma and bone metastasis foci of lung cancer patients, and positively correlates with bone metastasis, thus can be used as a biomarker for detecting and diagnosing bone metastasis. Further studies have proved that the differentiation of macrophages to osteoclasts induced by IBSP is a necessary and sufficient condition for promoting lung cancer bone metastasis, thus IBSP inhibitors can inhibit bone metastasis. In addition, the present inventors first found that IBSP can directly induce the positive differentiation of macrophages to osteoclasts by regulating the Rac1-NFAT signaling pathway, thus inhibiting Rac1 can block the lung cancer bone metastasis induced by IBSP. The present application provides an effective target for diagnosing and treating lung cancer bone metastasis, and provides a new method for the prevention, diagnosis and treatment of bone metastasis.

The application relates to the technical field of tumor biology, and particularly discloses a screening method of a candidate compound for reducing docetaxel resistance of prostate cancer patients and application. The screening method comprises the following steps: detecting the influence of a compound on the combination of B-cell lymphoma-2 protein and UBR family protein IV; and when the compound promotes the combination of B-cell lymphoma-2 protein and UBR family protein IV, the compound is a candidate compound. The application screens the candidate compound for reducing docetaxel resistance of prostate cancer patients by detecting the influence of the compound on the combination of B-cell lymphoma-2 protein and UBR family protein IV, so that the intrinsic and adaptive DTX resistance induced by TGF-beta in PCa bone metastasis is overcome.

The invention relates to a nano compound loaded with EZH2siRNA and docetaxel, which is characterized in that a zeolite imidazole skeleton (ZIF-8) is used as a carrier for siRNA delivery, then siRNA (ZIF)-8NPs is coated by using double-layer lipid, and meanwhile, the docetaxel (DTXL) is loaded in the double-layer lipid. The nano-composite loaded with EZH2siRNA and docetaxel has the beneficial effects that 1, the nano-composite loaded with EZH2siRNA and docetaxel is small in side effect as a drug, and the drug distribution at the bone metastatic focus of prostate cancer is relatively good; 2, the ZIF-8 has strong positive charges and can effectively adsorb siRNA with negative charges; 3, the nano drug loading system with a core-shell structure can more efficiently co-deliver siRNA and docetaxel, the core structure ZIF-8 can effectively load siRNA, and a shell lipid bilayer can effectively deliver a chemotherapeutic drug DTXL; and 4, the nano-composite loaded with the EZH2siRNA and the docetaxel is used as a medicine, so that the targeting property is high, and alendphosphate groups in middle and outer layer lipid DOPE-PEG-Alendronate can be effectively distributed to bone metastasis lesion in a targeting manner.

The invention relates to a tumor bone metastasis prediction system and method based on a bone metastasis specific bone marker. The system comprises a calculation module used for calculating the sensitive weight of each common marker for the same cancer according to the metabolic rate of a plurality of patients for each common marker and the number of the plurality of patients; the compensation module is used for determining a compensation coefficient of each specific marker for the same cancer on the basis of the difference between the detection value of each specific marker of the same patient and historical detection data; the determining module is used for determining a target coupling coefficient of each specific marker according to the relevancy between each specific marker and each common marker of the plurality of patients; and the analysis module is used for carrying out risk analysis according to the sensitive weight, the compensation coefficient, the target coupling coefficient and the target growth speed of each common marker to obtain an analysis result. According to the application, the change synchronism of the common marker and the specific marker can be quantified, the early bone metastasis detection capability is improved, and the misjudgment rate is reduced.

The invention relates to the field of image processing, and discloses a bone metastasis detecting and positioning system and method based on SPECT bone imaging. The system performs multi-scale feature extraction and feature processing on a to-be-detected image through a feature pyramid network to obtain a multi-scale feature map; then, metabolic features, morphological features and uptake mode features are extracted from the multi-scale feature map through a bone specificity feature model, and progressive fusion is carried out on the metabolic features, the morphological features and the uptake mode features to obtain a bone specificity enhanced feature map; performing feature extraction and feature fusion on the bone specificity enhanced feature map through a mixed feature fusion model to obtain mixed fusion features; and finally, probabilistic reasoning and dual uncertainty quantification processing are carried out on the mixed fusion features through a probabilistic reasoning network, a bone metastasis detection result is determined, high-precision detection and positioning of bone metastasis lesions are achieved, and the problems that in the prior art, lesions of different sizes cannot be effectively recognized, and global perception ability is lacked are effectively solved.

The aqueous pharmaceutical formulation with improved stability comprises denosumab and a poloxamer, and preferably a histidine buffer and / or a sugar or sugar alcohol. The formulation is for use in the treatment or prevention of skeletal-related events associated with osteoporosis, reduced bone mass, multiple myeloma, solid tumor bone metastasis, giant cell tumor of bone, or hypercalcemia.

The application relates to a tumor bone metastasis prediction system and method based on bone metastasis specific bone markers. The system comprises a calculation module, which calculates the sensitive weight of each common marker for the same cancer according to the metabolic speed of each common marker of a plurality of patients and the number of the plurality of patients; a compensation module, which determines the compensation coefficient of each specific marker for the same cancer based on the difference between the detection value of each specific marker of the same patient and historical detection data; a determination module, which determines the target coupling coefficient of each specific marker according to the correlation between each specific marker and each common marker of a plurality of patients; and an analysis module, which performs risk analysis according to the sensitive weight, the compensation coefficient, the target coupling coefficient and the target growth speed of each common marker to obtain an analysis result. The application can quantify the synchronism of the changes of the common markers and the specific markers, improve the early bone metastasis detection capability and reduce the misjudgment rate.

The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER-breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER-breast cancer metastasis.

The present application discloses a bone-targeting radiopharmaceutical or imaging agent and a use thereof. The bone-targeting radiopharmaceutical or imaging agent can be used for the treatment or diagnosis of bone diseases, such as bone metastasis from a tumor.

The invention belongs to the technical field of tumor model construction, and discloses a lung adenocarcinoma animal model with high bone metastasis, a cell line and a construction method and application thereof. The lung adenocarcinoma animal model with high bone metastasis is provided through multi-generation in-vivo directional screening, and the construction method is efficient, controllable, high in repeatability, capable of remarkably improving the tumor formation efficiency and rate, capable of being applied to immune healthy mice, low in cost and high in stability. And further extracting tumor cells from the bone metastasis lesion of the animal model to obtain the mouse lung adenocarcinoma cell line with high bone metastasis. The cell line has the advantages of being excellent in bone metastasis performance, stable in phenotype, heritable and the like, can be connected with an existing research system, has universality and economical efficiency, and can efficiently meet the requirement of bone metastasis mechanism research on a high-specificity model. The method can be applied to the fields of construction of tumor animal models or cell lines of bone metastasis, screening or development of lung adenocarcinoma drugs and the like.

The invention relates to a multi-target molecular ligand as well as a preparation method and application thereof. The multi-targeting molecular ligand disclosed by the invention aims at prostate cancer and bone metastasis thereof, and the ligand simultaneously contains a polypeptide chain Glu-urea-Lys (ACUPA) capable of being recognized by a prostate specific membrane antigen (PSMA), is used for targeting diphosphoric acid of hydroxyapatite nanocrystals in bones, and is also combined with an anisidine fragment which is specifically combined with a Sigma-1 receptor. The multi-target molecular ligand can efficiently mark radionuclide and has excellent radiation stability, cell and animal experiments prove that the multi-target molecular ligand can be efficiently taken by PSMA positive prostate cancer RM-1 cells, RM-1 subcutaneous tumor models and RM-1 tibial metastatic tumor models, and can be used for developing diagnosis and treatment of PSMA positive prostate cancer and bone metastasis thereof, and diagnosis and treatment integration is achieved.